Loading…
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $31M | $-229M | $-232M | $-243M | -75.8% | -27.5% | 77.2% |
| 2024 | $43M | $-129M | $-131M | $-130M | -38.9% | -6.0% | 84.9% |
| 2023 | $46M | $-69M | $-71M | $-2M | -26.6% | 11.1% | -30.8% |
| 2022 | $41M | $-97M | $-102M | $-67M | -106.1% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 41.40 | 46.02 | 43.27 | 31.37 |
| Operating Revenue | - | 41.40 | 46.02 | 43.27 | 31.37 |
| Cost Of Revenue | - | 8.33 | 4.63 | 3.71 | 2.07 |
| Gross Profit | - | 33.08 | 41.39 | 39.56 | 29.30 |
| Operating Expense | - | 112.02 | 116.45 | 185.42 | 272.74 |
| Research And Development | - | 49.64 | 64.66 | 132.93 | 221.04 |
| Selling General And Administration | - | 60.32 | 51.79 | 52.49 | 51.70 |
| Total Expenses | - | 120.34 | 121.08 | 189.13 | 274.80 |
| Operating Income | - | -78.94 | -75.07 | -145.85 | -243.43 |
| Total Operating Income As Reported | - | -99.64 | -75.07 | -145.85 | -243.43 |
| EBITDA | - | -96.62 | -69 | -129.23 | -229.34 |
| Normalized EBITDA | - | -74.36 | -67.65 | -129.23 | -229.34 |
| EBIT | - | -99.06 | -69.46 | -130.77 | -231.65 |
| Interest Income | - | 2.13 | 6.95 | 15.09 | 11.78 |
| Interest Expense | - | 3.19 | 1.25 | 0.01 | 0.03 |
| Net Interest Income | - | -1.06 | 5.70 | 15.07 | 11.75 |
| Other Income Expense | 2.06 | -22.26 | -1.35 | - | - |
| Interest Income Non Operating | - | 2.13 | 6.95 | 15.09 | 11.78 |
| Interest Expense Non Operating | - | 3.19 | 1.25 | 0.01 | 0.03 |
| Net Non Operating Interest Income Expense | - | -1.06 | 5.70 | 15.07 | 11.75 |
| Pretax Income | - | -102.25 | -70.71 | -130.78 | -231.68 |
| Tax Provision | - | 0 | 0.08 | 0.09 | 0.28 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -0.28 | 0 | 0 |
| Net Income Continuous Operations | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income From Continuing And Discontinued Operation | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income From Continuing Operation Net Minority Interest | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income Common Stockholders | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Net Income Including Noncontrolling Interests | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Normalized Income | - | -80 | -69.73 | -130.87 | -231.96 |
| Diluted NI Availto Com Stockholders | - | -102.25 | -70.80 | -130.87 | -231.96 |
| Basic Average Shares | - | 37.32 | 38.90 | 56.30 | 73.25 |
| Diluted Average Shares | - | 37.32 | 38.90 | 56.30 | 73.25 |
| Reconciled Depreciation | - | 2.45 | 0.46 | 1.54 | 2.31 |
| Reconciled Cost Of Revenue | - | 7.93 | 4.63 | 3.71 | 2.07 |
| Total Unusual Items | - | -22.26 | -1.35 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | - | -22.26 | -1.35 | 0 | 0 |
| Special Income Charges | - | -22.26 | -1.35 | 0 | 0 |
| Other Special Charges | -2.06 | 1.56 | 1.35 | - | - |
| Impairment Of Capital Assets | 0 | 20.70 | 0 | - | - |
| Depreciation Amortization Depletion Income Statement | 2.46 | 2.05 | 0 | - | - |
| Depreciation And Amortization In Income Statement | 2.46 | 2.05 | 0 | - | - |
| General And Administrative Expense | - | 34.82 | 40.10 | 52.36 | 51.61 |
| Other Gand A | - | 34.82 | 40.10 | 52.36 | 51.61 |
| Selling And Marketing Expense | - | 25.51 | 11.69 | 0.13 | 0.09 |
| Amortization | 2.46 | 2.05 | 0 | - | - |
| Amortization Of Intangibles Income Statement | 2.46 | 2.05 | 0 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| EyePoint, Inc.this co. | EYPT | $1.0B | -4.43 | 3.36 | -75.8% | -4.13 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.1B | 1916.51 | 77.56 | 4.0% | 28.56 |
| Collegium Pharmaceutical, Inc. | COLL | $1.1B | 16.86 | 3.51 | 20.8% | 4.10 |
| CONMED Corporation | CNMD | $1.1B | 22.48 | 1.02 | 4.6% | 10.49 |
| Azenta, Inc. | AZTA | $1.1B | -18.88 |
| - |
| - |
| - |
| - |
| - |
| 0.61 |
| -3.2% |
| 20.85 |
| The Pennant Group, Inc. | PNTG | $1.0B | 35.40 | 3.15 | 8.9% | 24.38 |
| QuidelOrtho Corporation | QDEL | $1.0B | -0.92 | 0.54 | -58.9% | -7.68 |
| Artivion, Inc. | AORT | $1.0B | 103.65 | 2.26 | 2.2% | 18.87 |
| Corvus Pharmaceuticals, Inc. | CRVS | $986M | -64.49 | 16.10 | -25.0% | -22.91 |
| Peer Median | - | 19.67 | 2.70 | 3.1% | 14.68 | |